CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

CareDx Reports Fourth Quarter and Full Year 2020 Results https://finance.yahoo.com/news/caredx-reports-fourth-quarter-full-210100080.html Recent Highlights: • Achieved total revenue of $58.6 million for the three months ended December 31, 2020, increasing 64% over prior year fourth quarter • Delivered record full year revenue of $192.2 million, an increase of 51% compared with full year 2019 revenue • Provided over 25,000 patient results in the fourth quarter and approximately 79,000 patient results in 2020 • Generated GAAP net loss of $3.5 million, non-GAAP net income of $4.3 million, and positive adjusted EBITDA of $4.9 million in the fourth quarter • As of December 31, 2020, over 55 U.S.-based transplant centers have adopted an AlloSure Kidney testing protocol • Received Medicare reimbursement pricing for AlloSure Heart       ....

BRIEF-Ark Investment Management Llc Reports A Passive Stake Of 10.54% In CareDx Inc As Of Jan. 31, 2021 https://pub.webull.com/us/news-html/12ba70cf914647c5afe835a27cedb190.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en Caredx jumps 10% after Cathie Wood’s ARK takes 10.5% stake https://seekingalpha.com/news/3660957-caredx-stock-rises-10-on-ownership-disclosure • ARK Investment Management discloses 5.19M share ownership in CareDX (NASDAQ:CDNA), representing 10.54%. • The shares contain voting power.

CareDx Announces Pricing of Public Offering of Common Stock https://finance.yahoo.com/news/caredx-announces-pricing-public-offering-035600029.html today announced the pricing of an underwritten public offering of 1,923,077 shares of its common stock at a public offering price of $91.00 per share. The gross proceeds to CareDx from this offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $175,000,007. In addition, CareDx has granted the underwriters a 30 day option to purchase up to 288,461 additional shares of its common stock offered in the public offering on the same terms and conditions. The offering is expected to close on or about January 25, 2021, subject to the satisfaction of customary closing conditions. ...

CareDx Announces Proposed Public Offering of Common Stock https://finance.yahoo.com/news/caredx-announces-proposed-public-offering-211400257.html ...today announced that it intends to offer and sell, subject to market and other conditions, up to $175.0 million of shares of its common stock in an underwritten public offering. CareDx also expects to grant the underwriters of the offering a 30 day option to purchase up to an additional $26.25 million of shares of its of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx. ...

👍

Im organ Bereich gibt es noch transmedics. Auch ein absoluter game changer. Das wird die Organspenden Revolutionieren!

CareDx Reports Preliminary Fourth Quarter and Full Year 2020 Results https://www.globenewswire.com/news-release/2021/01/11/2156127/0/en/CareDx-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2020-Results.html

CareDx Agrees to Acquire TransChart and Expands EMR Connectivity to Over 90 Centers http://www.globenewswire.com/news-release/2021/01/08/2155496/0/en/CareDx-Agrees-to-Acquire-TransChart-and-Expands-EMR-Connectivity-to-Over-90-Centers.html Acquisition will build on CareDx’s digital capabilities and continue deepening the moat with transplant centers ...

CareDx Announces AlloID and Exclusive Partnership with IDbyDNA https://www.globenewswire.com/news-release/2021/01/07/2154794/0/en/CareDx-Announces-AlloID-and-Exclusive-Partnership-with-IDbyDNA.html AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx’s Innovation in Multi-Modality Surveillance Care ...

CareDx’s AlloSeq HCT Wins Tender for French Stem Cell Transplant Patient Surveillance https://www.globenewswire.com/news-release/2021/01/04/2152520/0/en/CareDx-s-AlloSeq-HCT-Wins-Tender-for-French-Stem-Cell-Transplant-Patient-Surveillance.html CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang ...

CareDx: Stock To Achieve Significant Long-Term Growth https://seekingalpha.com/article/4397022-caredx-stock-to-achieve-significant-long-term-growth Summary CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx. While the company's growth is strong and above-average, the valuation and near overbought level needs to be considered. ...

CareDx Celebrates the Long-Awaited Passage of the Immuno Bill http://www.globenewswire.com/news-release/2020/12/22/2149535/0/en/CareDx-Celebrates-the-Long-Awaited-Passage-of-the-Immuno-Bill.html Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients ...

CareDx price target raised to $75 from $62 at Raymond James https://thefly.com/landingPageNews.php?id=3210563&headline=CDNA-CareDx-price-target-raised-to--from--at-Raymond-James